stockrowBeam Therapeutics Inc.
BEAM Healthcare Biotechnology
Beam Therapeutics Inc.’s revenue for fiscal 2025 (year ended December 2025) was $139.7 million, up 120.0% from fiscal 2024.
- Revenue
- −96.8%
- EPS
- −16.7%
- Free cash flow
- −29.5%
Quarter to September 2026, against a year earlier
Follow BEAM
Alert me
Beam Therapeutics Inc. (BEAM) EPS (diluted)
Beam Therapeutics Inc.'s EPS (diluted) for fiscal 2025 was −$0.81, compared with −$4.58 in fiscal 2024. Over the twelve months to 30 September 2026 it was −$1.04. Over the past ten years it has ranged from −$40.34 (fiscal 2018) to −$0.19 (fiscal 2017); the current reading is higher than 89% of that period. Beam Therapeutics Inc. ranks 210th of 580 Biotechnology companies by EPS (diluted).
EPS (diluted), annual
Embed this chart
Annual newest first
| Period | EPS (diluted) | Change |
|---|---|---|
| FY2025 | −$0.81 | — |
| FY2024 | −$4.58 | — |
| FY2023 | −$1.72 | — |
| FY2022 | −$4.13 | — |
| FY2021 | −$5.77 | — |
| FY2020 | −$4.19 | — |
| FY2019 | −$14.05 | — |
| FY2018 | −$40.34 | — |
| FY2017 | −$0.19 | — |
Quarterly newest first
| Period | EPS (diluted) | Change |
|---|---|---|
| Sep 2026 | −$1.28 | — |
| Jun 2026 | −$1.18 | — |
| Mar 2026 | −$0.91 | — |
| Dec 2025 | $2.33 | — |
| 27 more quarters | Free account |
Against its own ten years
EPS (diluted) against peers
| Company | EPS (diluted) |
|---|---|
| BEAM Beam Therapeutics Inc. | −$1.04 |
| NAMS NewAmsterdam Pharma Company N.V. compare | −$1.69 |
| ZLAB Zai Lab Limited Unsponsored ADR compare | −$1.71 |
| XNCR Xencor, Inc. compare | −$2.17 |
| MBX MBX Biosciences, Inc. compare | −$2.41 |
| VRDN Viridian Therapeutics, Inc. compare | −$3.37 |
| RCUS Arcus Biosciences, Inc. compare | −$3.63 |
| IDYA IDEAYA Biosciences, Inc. compare | −$4.49 |
| TLX Telix Pharmaceuticals Limited compare | — |
What EPS (diluted) is
Diluted EPS tells an investor how much profit a company earned for each share, counting the extra shares that options and convertible securities could create.
Reported line item
More on BEAM
- Revenue
- Net income
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- The full statement